QUOTE AND NEWS
Benzinga  Mar 26  Comment 
pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced the completion of the originally targeted enrollment of 120 patients in its pivotal Phase III...
Benzinga  Oct 27  Comment 
pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that it has received the $25 million milestone payment under its out-license of ILUVIEN® for...
SeekingAlpha  Aug 12  Comment 
By Dr. Paul Nunzio De Santis, Pharm.D: As pSivida awaits an FDA decision on Iluvien with a PDUFA date on September 26, 2014, that if approved will trigger a $25M milestone payment from commercialization partner Alimera Sciences (NASDAQ:ALIM) and...
StreetInsider.com  Jun 30  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/pSivida+Corp.+%28PSDV%29+Reports+Successful+Completion+of+ILUVIEN+Mutual+Recognition+Procedure/9622725.html for the full story.
StreetInsider.com  Jun 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/pSivida+Corp.+%28PSDV%29+Receives+Marketing+Approval+for+ILUVIEN+in+Italy/9604463.html for the full story.
StreetInsider.com  Apr 14  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/pSivida+Corp.+%28PSDV%29+Receives+PDUFA+Date+for+ILUVIEN/9375968.html for the full story.
SeekingAlpha  Feb 8  Comment 
pSivida Corp (PSDV) F2Q 2014 Earnings Call February 7, 2014 4:30 PM ET Executives Lori Freedman - IR Paul Ashton - President and CEO Leonard Ross - VP, Finance and Principal Financial Officer Analysts Suraj Kalia -...
StreetInsider.com  Feb 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/pSivida+Corp.+%28PSDV%29+Reports+In-Line+Q2+Loss+of+13cShare/9140179.html for the full story.
DailyFinance  Jan 13  Comment 
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial orders of...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki